Mo Gawdat
Former Chief Business Officer, Google X | International Bestselling Author: Scary Smart, Solve for Happy & Unstressable | AI Visionary & Serial Entrepreneur
2012 Nobel Laureate in Physiology or Medicine | Inventor of iPS Cell Technology | Senior Investigator, Gladstone Institutes | Professor, UCSF
Shinya Yamanaka rewrote the rules of biology when he discovered that adult cells could be reprogrammed into stem cells capable of becoming any tissue in the body. His invention of iPS cell technology earned him the 2012 Nobel Prize in Physiology or Medicine and ignited a global revolution in regenerative medicine, disease modeling, and cell therapy. In his keynotes, he translates that landmark science into a compelling vision of where medicine is headed — and what it takes to get there.
Want to book Shinya Yamanaka as a speaker for your event? Please provide the info below and we’ll get in touch within 24h:
Shinya Yamanaka is one of the most transformative biomedical scientists of the modern era, whose single discovery upended a century of biological dogma and opened an entirely new frontier in medicine. Born in Higashiosaka, Japan, he earned his M.D. from Kobe University and his Ph.D. from Osaka City University before training as an orthopedic surgeon — a clinical background that would shape his lifelong motivation to translate science into treatments for patients with incurable diseases. After postdoctoral work at the Gladstone Institutes in San Francisco, he built his research program across institutions in Japan and the United States, eventually joining Kyoto University in 2004 and the Gladstone Institutes as a Senior Investigator in 2007.
Nobel Prize speaker Shinya Yamanaka is best known for a discovery made in 2006 that the scientific community initially found difficult to believe: that fully specialized adult cells — skin cells — could be reprogrammed back into an embryonic-like state capable of becoming virtually any cell in the body. By introducing just four transcription factors, now known worldwide as the Yamanaka factors, he created what he called induced pluripotent stem cells, or iPS cells. The implications were immediate and sweeping. For the first time, researchers could generate patient-specific stem cells without using embryos, bypassing both the ethical controversies and the immunological barriers that had long constrained the field.
In 2012, Yamanaka was awarded the Nobel Prize in Physiology or Medicine, shared with Sir John Gurdon, for the discovery that mature cells can be reprogrammed to become pluripotent. The prize recognized work that had already reshaped developmental biology globally and catalyzed a new generation of research into disease modeling, drug discovery, and regenerative medicine. Alongside the Nobel, his career recognition includes the Albert Lasker Basic Medical Research Award, the Wolf Prize in Medicine, the Millennium Technology Prize, the Kyoto Prize, and the Gairdner International Award, among many others. He is a member of the National Academy of Sciences, the National Academy of Medicine, and the Gladstone Institutes, where he continues his research as the L.K. Whittier Foundation Investigator in Stem Cell Biology.
As a speaker, Shinya Yamanaka delivers one of the most compelling stories in contemporary science: how curiosity, persistence, and a doctor’s desire to help patients led to a discovery that is now driving breakthroughs in Alzheimer’s disease, Parkinson’s, diabetes, and cancer. He speaks with clarity and humility about the scientific process, the long arc from fundamental research to clinical application, and the ethical dimensions of stem cell technology. For healthcare executives, life science investors, and research leaders, his keynotes offer both a landmark scientific narrative and a forward-looking perspective on where regenerative medicine is headed next.
In 2006, Yamanaka identified four transcription factors capable of reverting specialized adult cells into a stem-cell state — a finding that defied decades of biological consensus. This keynote traces the arc of that discovery: from early observations in the lab to global clinical application, from a young orthopedic surgeon's desire to help patients to a Nobel Prize. Audiences gain a rare firsthand account of how paradigm-shifting science actually happens, and what it reveals about the future of medicine.
iPS cell technology has moved from laboratory curiosity to clinical pipeline with remarkable speed. Yamanaka surveys the current frontier of regenerative medicine — cell therapies for Parkinson's disease, macular degeneration, heart failure, and beyond — and examines what scientific, regulatory, and commercial challenges remain before these treatments reach patients at scale. An essential talk for healthcare executives, life science investors, and anyone building strategy in the biomedical space.
One of the most powerful applications of iPS cell technology is the ability to grow disease in a dish — generating patient-specific cells that carry the exact genetic mutations driving Alzheimer's, ALS, rare diseases, and more. Yamanaka explains how this platform is making drug discovery faster, more accurate, and more human, and why patient-derived cell models are increasingly replacing animal studies across the pharmaceutical industry. A forward-looking keynote for R&D leaders, biotech founders, and medical innovators.
Every powerful technology carries ethical weight, and stem cell science is no exception. Drawing on his own experience navigating public debate, regulatory scrutiny, and international collaboration, Yamanaka reflects on how scientists, institutions, and policymakers can work together responsibly to advance transformative research. A nuanced and deeply personal talk that speaks directly to leaders who must balance innovation with accountability — in science, in business, and in society.
| Basic Data Protection Information | |
|---|---|
| Data controller | AURUM SPEAKERS BUREAU S.L. |
| Address | Parc Audiovisual de Catalunya 1, Oficina S11, 08225 Terrassa, Spain |
| Purposes | We will use your data to respond to your requests and deliver our services to you. |
| Marketing | We will only send you marketing correspondence if you have given your prior consent, which you can do by ticking the box for that purpose. |
| Lawful basis | We will only process your data if you have given your prior consent, which you can do by ticking the box for that purpose. |
| Recipients | Generally, only our members of staff who have been duly authorised may access the data that you have provided. |
| Your Rights | You have the right to know what information we hold about you, to rectify it and to erase it, as explained in the additional information available on our website. |
| Additional Information | For more information, please see “PRIVACY POLICY” on our website. |